記事
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
デジタルデータあり（Crossref）
すぐに読む
CiNii Research
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
- 資料種別
- 記事
- 著者
- Hugh Calkinsほか
- 出版者
- Massachusetts Medical Society
- 出版年
- 2017-04-27
- 資料形態
- デジタル
- 掲載誌名
- New England Journal of Medicine 376 17
- 掲載ページ
- p.1627-1636
全国の図書館の所蔵
国立国会図書館以外の全国の図書館の所蔵状況を表示します。
所蔵のある図書館から取寄せることが可能かなど、資料の利用方法は、ご自身が利用されるお近くの図書館へご相談ください
書誌情報
この資料の詳細や典拠（同じ主題の資料を指すキーワード、著者名）等を確認できます。
デジタル
- 資料種別
- 記事
- 著者標目
- 出版年月日等
- 2017-04-27
- 出版年（W3CDTF）
- 2017-04-27
- タイトル（掲載誌）
- New England Journal of Medicine
- 巻号年月日等（掲載誌）
- 376 17
- 掲載巻
- 376
- 掲載号
- 17
- 掲載ページ
- 1627-1636
- 掲載年月日（W3CDTF）
- 2017-04-27
- ISSN（掲載誌）
- 00284793
- 出版事項（掲載誌）
- Massachusetts Medical Society
- 対象利用者
- 一般
- DOI
- 10.1056/nejmoa1701005
- 作成日（W3CDTF）
- 2017-03-19
- 参照
- Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administrationFactors associated with silent cerebral events during atrial fibrillation ablation in patients on uninterrupted oral anticoagulationOptimal Anticoagulant Strategy for Periprocedural Management of Atrial Fibrillation Ablation: A Systematic Review and Network Meta-AnalysisDifferent Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation ProcedureEdoxaban eliminates hypercoagulability evoked by transient temperature changes in human whole bloodUninterrupted Direct Oral Anticoagulant and Warfarin Administration in Elderly Patients Undergoing Catheter Ablation for Atrial FibrillationIdarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance StudyIdarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance StudyProthrombotic Responses After Catheter Ablation for Atrial Fibrillation During Uninterrupted Oral Anticoagulant Agent AdministrationClinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation追加発言2 心房細動カテーテルアブレーションと周術期抗凝固治療Periprocedural Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation Without Discontinuation of a Vitamin K Antagonist and Direct Oral AnticoagulantsUninterrupted Direct Oral Anticoagulants Without a Change in Regimen for Catheter Ablation for Atrial Fibrillation Is an Acceptable ProtocolCatheter Ablation Energy Sources and Myocardial Injury and Coagulation Biomarkers During Uninterrupted Periprocedural Edoxaban Use : A Subanalysis of KYU-RABLE<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac ArrhythmiasReal-world investigation on anticoagulation management before and after catheter ablation for atrial fibrillation in Japan—periprocedural and long-term outcomesIs Transesophageal Echocardiography Necessary in Every Case of Atrial Fibrillation Ablation?Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial FibrillationPercutaneous Simple Lead Traction Is a Feasible and Effective Method for Right Ventricular Lead PerforationsEfficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation ― The Prospective KYU-RABLE Study ―カテーテルアブレーションと抗凝固療法
- 連携機関・データベース
- 国立情報学研究所 : CiNii Research
- 提供元機関・データベース
- CrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossref